AHR vs WELL: How American Healthcare REIT and Welltower Compare (2026)
Last updated August 2026
Short answer
WELL is the larger of the two ($168.93B market cap): the incumbent the market prices for continued execution (71.58x forward earnings, beta 0.76). AHR is the smaller challenger ($10.70B), priced similarly on forward earnings (64.53x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
AHR vs WELL: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | AHR | WELL | What it tells you |
|---|---|---|---|
| Market cap | $10.70B | $168.93B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 64.53 | 71.58 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 94.07 | 105.13 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.77 | 0.76 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 83% of range | 78% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 3.03 | 3.77 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how AHR and WELL affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AHR and WELL share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AHR and WELL exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does American Healthcare REIT (AHR) do?
American Healthcare REIT owns and operates a diversified clinical healthcare property portfolio across the United States, the United Kingdom and the Isle of Man. It reports in four segments: integrated senior health campuses (ISHC, essentially the Trilogy Health Services platform of 130-plus combined senior living and skilled nursing campuses in Ohio, Kentucky, Indiana, Michigan and Wisconsin), senior housing operating properties (SHOP), outpatient medical buildings, and triple-net leased facilities. ISHC and SHOP together produce the large majority of net operating income, which is the single most important fact about the company: those are RIDEA-style structures where AHR receives the property's operating profit after staffing, food and insurance costs, not a fixed rent check. AHR became sole owner of Trilogy REIT Holdings in September 2024 after buying out the remaining 24% minority interest, which concentrated the earnings power (and the operating risk) inside the company.
What does Welltower (WELL) do?
Welltower Inc. is the largest healthcare REIT in the world, owning a portfolio of senior housing, assisted living, post-acute and long-term care, and outpatient medical real estate across the United States, the United Kingdom, and Canada. It makes money in two main ways: through its Senior Housing Operating Portfolio (SHOP), where it shares directly in the net operating income that property operators generate from residents, and through rents on triple-net leased seniors housing and care facilities plus outpatient medical buildings. Because SHOP income flows through to Welltower rather than being fixed rent, rising occupancy and room rates translate quickly into higher earnings, which is why the operating portfolio has become the company's main growth engine.
AHR vs WELL: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- AHR drivers: The 80-plus demographic wave meeting a supply drought; Operating leverage in the RIDEA and Trilogy platforms.
- WELL drivers: Aging-demographics senior-housing tailwind; Operating-portfolio NOI growth.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The same RIDEA structure that creates the upside removes the cushion on the way down: if occupancy stalls or wage and insurance inflation reaccelerate, NOI falls straight to the bottom line with no lease floor underneath it. For WELL, welltower's share price is sensitive to interest rates, since higher rates raise borrowing costs and make REIT dividend yields less competitive against bonds.
AHR or WELL: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick AHR if you believe its drivers more; WELL if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AHR and WELL guides.
AHR vs WELL: the full fundamentals
AHR. For a REIT, FFO and AFFO matter more than reported EPS because large non-cash depreciation charges push GAAP net income far below actual cash generation, which is why AHR's headline P/E near 90 looks nothing like its high-20s multiple of normalized FFO. The multiple is still a premium to the healthcare REIT group, and the market is effectively underwriting several more years of the double-digit same-store NOI growth AHR has delivered for nine straight quarters. The unusual feature versus most REITs is the yield: under 2% means this is being priced as a growth equity rather than an income holding.
WELL. Healthcare REITs are valued on funds from operations (FFO) rather than EPS, because standard net income is weighed down by large non-cash depreciation charges on real estate. For Welltower the most important operating metric is same-store NOI growth in the Senior Housing Operating Portfolio, since that captures how much extra income the company earns as occupancy and room rates rise. Welltower trades at a notably higher FFO multiple, and a lower dividend yield, than most healthcare REIT peers, reflecting the market's confidence in its senior-housing growth, its scale, and its balance sheet; that premium is part of the investment case and part of the risk.
Headline figures (approximate, August 2026): AHR shows revenue (ttm) ~$2.37B, up ~12.7% year over year, 2026 normalized ffo guidance ~$2.03 to $2.09 per diluted share (Q1 2026 NFFO was ~$0.50, up over 30%), same-store noi growth ~12.1% in Q1 2026; full-year 2026 guidance ~9.0% to 12.0%, dividend ~$1.00 annualized ($0.25 quarterly), ~1.8% yield; WELL shows normalized ffo per share (2025) $5.29 (+~22.5%), 2026 normalized ffo guidance $6.09 to $6.25, shop same-store noi growth (q4 2025) ~20.4% YoY, revenue (2025) ~$10.84 billion (+~36%).
The bottom line: AHR vs WELL
AHR and WELL are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AHR and WELL exposure against your real portfolio. It is not an investment adviser.
Wondering how AHR or WELL fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in American Healthcare REIT with AI
Connect the broker you already use and ask Walnut's AI how AHR fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between AHR and WELL?
+
American Healthcare REIT owns and operates a diversified clinical healthcare property portfolio across the United States, the United Kingdom and the Isle of Man. Welltower Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is AHR or WELL the better stock?
+
Neither is universally better. WELL is the larger incumbent; AHR is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, AHR or WELL?
+
On forward P/E (as of August 2026), AHR trades at 64.53x and WELL at 71.58x, so AHR is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both AHR and WELL?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of AHR vs WELL?
+
AHR: The same RIDEA structure that creates the upside removes the cushion on the way down: if occupancy stalls or wage and insurance inflation reaccelerate, NOI falls straight to the bottom line with no lease floor underneath it. Skilled nursing and the ISHC segment carry meaningful Medicare and Medicaid reimbursement exposure, so federal or state rate decisions and any tightening of Medicaid funding are genuine earnings risks that AHR does not control. Valuation is its own risk factor: at roughly 27 times 2026 NFFO guidance and a GAAP P/E in the high 80s, the shares leave little room for a guidance miss, and the sub-2% dividend yield offers little support if the growth narrative cools. Concentration matters too, with the Trilogy platform in five Midwestern states responsible for a large share of portfolio NOI. Finally, as a heavily acquisitive REIT, AHR depends on continued access to equity and debt on favorable terms, and a change in rates or sentiment toward senior housing would make the external growth engine much more expensive to run. WELL: Welltower's share price is sensitive to interest rates, since higher rates raise borrowing costs and make REIT dividend yields less competitive against bonds. The senior-housing operating model also carries labor cost and staffing pressures and depends on occupancy holding up, so a weaker demand environment or wage inflation could compress margins. The stock trades at a premium valuation relative to many healthcare REIT peers, which leaves limited room for disappointment and makes it vulnerable to multiple compression. The company is also deploying capital aggressively, so acquisition execution, integration, and the cost of financing that growth are real risks if returns on new investments fall short.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell AHR or WELL; figures are approximate and dated (as of August 2026). Verify current data before investing.